Strategic Acquisition Trilogy Writing & Consulting was acquired by Indegene in March 2024, signaling access to broader life sciences commercialization resources and potential cross-sell opportunities for end-to-end clinical documentation, medical writing, and regulatory consulting services.

Scale and Presence With over 80 writers across three international offices (Germany, UK, and US), Trilogy demonstrates scalable capacity and global delivery capabilities that can support multinational pharmaceutical and CRO clients seeking flexible, on-demand writing talent.

Regulatory Focus Specialization in clinical regulatory documentation and a proactive, story-driven writing approach positions Trilogy to target sponsors looking to shorten review cycles, reduce clarifying questions, and accelerate regulatory approvals.

Financial Footing Parent company integration and a revenue range of 500M to 1B suggest strong financial backing and potential for larger, multi-year outsourcing engagements, enabling longer-term contracts and expanded service suites.

Tech-Enabled FA Adoption of a tech stack including Google Fonts, Analytics tools, and UX-oriented components indicates a capability to support sponsor teams with streamlined deliverables and potentially scalable digital collaboration in writing programs.